MedTrace Logo

Mesenchymal Stromal Cells for Ischemic Stroke

NCT01922908 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2018-04-18

No results posted yet for this study

Summary

The purpose of this study is to determine if mesenchymal stem cells given by IV is feasible and safe in patients with recent ischemic stroke and to decide the maximum tolerated dose when given between 3-10 days after an ischemic stroke.

Conditions

Interventions

BIOLOGICAL

MSC Infusion

Allogeneic bone marrow derived mesenchymal stem cells given in one dose 3-10 days after stroke symptom onset

BIOLOGICAL

Placebo Comparator

Normal saline

Sponsors & Collaborators

  • Sean Savitz

    lead OTHER

Principal Investigators

  • Sean Savitz, MD · The University of Texas Health Science Center, Houston

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
83 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2018-12-31
Completion
2018-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01922908 on ClinicalTrials.gov